Regulación y derecho · 13/9/20101 min de lectura
Intent To Grant Field of Use Exclusive License to U.S. Government-Owned Patents
Traducción automática local · Idioma original de la fuente
Resumen
In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7 (a)(1)(i) and 404.7(b)(1)(i), announcement is made of the intent to grant a field of use exclusive, revocable license for the field of prevention and/or therapeutic treatment of vaccinia virus infections or other orthopoxvirus infections to the inventions claimed in U.S. Patent No. 6,451,309 entitled "Prophylactic and Therapeutic Monoclonal Antibodies," issued September 17, 2002, and U.S. Patent No. 6,620,412 entitled "Prophylactic and Therapeutic Monoclonal Antibodies," issued September 16, 2003, which is a continuation of U.S. Patent No. 6,451,309, and related foreign patents and patent applications (PCT/ US2001/04520) to Biofactura, Inc., with its principal place of business at 9430 Key West Avenue, Suite 125, Rockville, MD 20850-6345.